1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. Healius Limited
  6. News
  7. Summary
    HLS   AU0000033359

HEALIUS LIMITED

(HLS)
  Report
Delayed Australian Stock Exchange  -  02:10 2022-07-01 am EDT
3.650 AUD   -0.54%
06/15HEALIUS : Update - Notification of buy-back - HLS
PU
06/13HEALIUS : Update - Notification of buy-back - HLS
PU
06/08HEALIUS : Update - Notification of buy-back - HLS
PU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Healius : Strategy Day Presentation

05/19/2022 | 07:55pm EDT

rsonale use nlyo

20 May 2022

Healius Strategy Day

use only

ersonal

2

Healius Strategy Day

Acknowledgement of country

We acknowledge the Gadigal People of the Eora Nation as the traditional custodians of the land on which we gather today, and pay our respects to their Elders - past, present and emerging

COVID collection moving to regular ACCs from dedicated drive-throughs
Growth in requests for testing of other respiratory viruses along with COVID - expected to continue through the winter

Trading update

Core businesses

Revenues in all divisions slowly trending up, but not yet returned to normal with

impacts from floods and extensive COVID / isolation requirements in every state

Q3 Pathology slightly ahead of Medicare data (as in the first half) and Imaging

also slightly ahead

Operational challenges and additional costs due to level of COVID infections e.g.

staff on sick leave, last-minute cancellations of surgery and imaging procedures

only

Expect demand to catch up to long-term trends with population growth, ageing

population, increasing p

revalence of chronic diseases and better survival rates. Also backlog in routine

Agilex's new large molecule laboratory, South Australia

services and known underdiagnosis of diseases

COVID-19 Pathology

use

After a strong January, COVID testing around 15k per working day through

February to April1 (as expected at 1H22 results)

ersonal

1 Working day calculation based on total revenue / number of working days. April has similar working day volumes to Feb-Mar but less total revenue with only 18 working days in the month

3 Healius Strategy Day

Long term growth trends and COVID impact

use only

ersonal

Historical growth trend

4

Healius Strategy Day

Healius investment proposition

Well positioned in attractive markets

only

Solid core market fundamentals

Scaled diagnostics operator

Defensible incumbent positions

use

Clear operating leverage

Double-digit ROIC growth opportunities

Early positions in emerging diagnostics (e.g. genomics)

ersonal

5

Healius Strategy Day

Ready to capture growth & create value

  • Ability to consolidate & integrate for network growth
  • Cost out track record
  • Compelling digital proposition and strategy
  • Customer-centricre-orientation
  • Balance sheet strength
  • Proven commitment to TSR

This is an excerpt of the original content. To continue reading it, access the original document here.

Disclaimer

Healius Limited published this content on 19 May 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 19 May 2022 23:54:04 UTC.


© Publicnow 2022
All news about HEALIUS LIMITED
06/15HEALIUS : Update - Notification of buy-back - HLS
PU
06/13HEALIUS : Update - Notification of buy-back - HLS
PU
06/08HEALIUS : Update - Notification of buy-back - HLS
PU
06/06HEALIUS : Update - Notification of buy-back - HLS
PU
06/03Healius Completes Acquisition of Fertility Clinic Chain, Provides Underlying Pre-Tax Ea..
MT
06/02HEALIUS : Update - Notification of buy-back - HLS
PU
05/30HEALIUS : Update - Notification of buy-back - HLS
PU
05/19HEALIUS : Strategy Day Presentation
PU
05/18Healius Reportedly Seeks Acquisitions
CI
05/18Healius Reportedly Seeks X-Ray Factor in Day Surgeries Sale Plan
CI
More news
Financials
Sales 2022 2 357 M 1 600 M 1 600 M
Net income 2022 297 M 202 M 202 M
Net Debt 2022 691 M 469 M 469 M
P/E ratio 2022 7,33x
Yield 2022 4,77%
Capitalization 2 078 M 1 410 M 1 410 M
EV / Sales 2022 1,17x
EV / Sales 2023 1,36x
Nbr of Employees 11 000
Free-Float 99,0%
Chart HEALIUS LIMITED
Duration : Period :
Healius Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends HEALIUS LIMITED
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 15
Last Close Price 3,65 AUD
Average target price 4,26 AUD
Spread / Average Target 16,7%
EPS Revisions
Managers and Directors
Malcolm W. Parmenter Chief Executive Officer, MD & Director
Maxine Jaquet Chief Financial & Operating Officer
Robert Hubbard Independent Non-Executive Chairman
Paul Francis Jones Independent Non-Executive Director
Gordon R. Davis Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
HEALIUS LIMITED-30.87%1 410
SONIC HEALTHCARE LIMITED-29.36%10 549
GUANGZHOU KINGMED DIAGNOSTICS GROUP CO., LTD.-25.09%5 799
SYNLAB AG-29.66%3 805
DR. LAL PATHLABS LIMITED-41.51%2 341
FULGENT GENETICS, INC.-44.81%1 684